Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.
Also called NCT02448641
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 163 participants
- Sponsor
- SanBio, Inc.
- Registry
-
NCT02448641
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02448641. Randomized; double masking; primary purpose treatment. Start 2016-03-08 (actual); primary completion 2018-12-05 (actual). Results posted on 2020-04-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
- Acronym
- ACTIsSIMA
- Condition
- Chronic Ischemic Stroke
- Intervention (Biological)
- SB623 Implant (2.5M)
- Intervention (Biological)
- SB623 Implant (5.0M)
- Intervention (Procedure)
- Sham surgery
- Lead sponsor
- SanBio, Inc.
- Collaborator
- Sumitomo Pharma America, Inc.
Record details
- Record id
cardio:ct-nct02448641- Content hash
e3546255b44233648e470b28290f97c50926752d38ee9e267f66de54d6c987f3